Diabetes Drugs Market - Global Production, Sales and Consumption Status and Prospects Professional Market Research Report 2018 - 2025

Download as PDF 

 Published: Aug-2018 |  Format: PDF | Genesis Market Insights |  Number of pages: 120

GLOBAL DIABETES DRUG MARKET was valued at USD 47.2 Billion in the year 2017. Global Diabetes Drug Market is further estimated to grow at a CAGR of 7.09% from 2018 to reach USD 70.9 Billion by the year 2023. North America region holds the highest market share in 2017 and Asia-Pacific is considered as the fastest growing market in the forecasted period. At a country level, developed markets the U.S. holds a substantial market share in 2017 and it is projected to grow at a gradual pace in the coming years. Abbott Laboratories (U.S.), Novartis AG (Switzerland), Novo Nordisk (Denmark), Bayer Healthcare AG (Germany) , Johnson & Johnson (U.S) and Sanofi (France) are some of the key players in the Diabetes Drug Market with Novo Nordisk (Denmark) holding the significant market share because of its better global presence both at production and at an operational level. Rising research and developm... Read more
Table of Content
Table 1: Diabetes Drugs Market, Global, Approved Indications for Lantus, 2017

Table 2: Diabetes Drugs Market, Global, Approved Indications for Levemir, 2017

Table 3: Diabetes Drugs Market, Global, Approved Indications for Tresiba, 2017

Table 4: Diabetes Drugs Market, Global, Approved Indications for Toujeo, 2017

Table 5: Diabetes Drugs Market, Global, Approved Indications for Humalog, 2017

Table 6: Diabetes Drugs Market, Global, Approved Indications for Novolog, 2017

Table 7: Diabetes Drugs Market, Global, Approved Indications for Apidra, 2017

Table 8: Diabetes Drugs Market, Global, Approved Indications for Victoza, 2017

Table 9: Diabetes Drugs Market, Global, Approved Indications for Trulicity, 2017

Table 10: Diabetes Drugs Market, Global, Approved Indications for Januvia, 2017

Table 11: Diabetes Drugs Market, Global, Approved Indications for Galvus, 2017

Table 12: Diabetes Drugs Market, Global, Approved Indications for Tradjenta, 2017

Table 13: Diabetes Drugs Market, Global, Approved Indications for Invokana, 2017

Table 14: Diabetes Drugs Market, Global, Approved Indications for Jardiance, 2017

Table 15: Diabetes Drugs Market, Global, Approved Indications for Farxiga, 2017

Table 16: Diabetes Drugs Market, Global, Approved Indications for Soliqua, 2017

Table 17: Diabetes Drugs Market, Global, Approved Indications for Xultophy, 2017

Table 18: Diabetes Drugs Market, Global, Approved Indications for Janumet, 2017

Table 19: Market, Global, Approved Indications for Qtern, 2017

Table 20: Diabetes Drugs Market, Global Annual Revenue Forecast for Key Products ($m), 2018–2023)

Table 21: Diabetes Drugs Market, Global, Generic Usage across Key Indications, 2017

Table 22: Diabetes Drugs Market, Global Annual Revenue within Diabetes by Company, 2018–2023

Table 23: AbbreviationsFigure 1: Diabetes Drugs Market, Global, Epidemiology Patterns for T1DM, 2018–2023

Figure 2: Diabetes Drugs Market, Global, Epidemiology Patterns for T2DM, 2018–2023

Figure 3: Diabetes Drugs Market, Global, Market Share Projections for Key Established Products, 2018–2023

Figure 4: Diabetes Drugs Market, Global, Market Share Projections for Key Upcoming Products, 2018–2023

Figure 5: Diabetes Drugs Market, Global, Percentage Change in Market Share for Key Products 2018–2023

Figure 6: Diabetes Drugs Market, Global, Key Marketed Products and Approved Indications, 2017

Figure 7: Diabetes Drugs Market, Global Annual Revenue for Lantus ($bn), 2017–2023

Figure 8: Diabetes Drugs Market, Global Annual Revenue for Levemir ($bn), 2017–2023

Figure 9: Diabetes Drugs Market, Global Annual Revenue for Tresiba ($bn), 2018–2023

Figure 10: Diabetes Drugs Market, Global Annual Revenue for Toujeo ($bn), 2015–2023

Figure 11: Diabetes Drugs Market, Global Annual Revenue for Humalog ($bn), 2017–2023

Figure 12: Diabetes Drugs Market, Global Annual Revenue for Novolog ($bn), 2017–2023

Figure 13: Diabetes Drugs Market, Global Annual Revenues for Apidra ($m), 2009–2023

Figure 14: Diabetes Drugs Market, Global Annual Revenues for Victoza ($bn), 2009–2023

Figure 15: Diabetes Drugs Market, Global Annual Revenue for Trulicity ($bn), 2014–2023

Figure 16: Diabetes Drugs Market, Global Annual Revenue for Januvia ($bn), 2017–2023

Figure 17: Diabetes Drugs Market, Global Annual Revenue for Galvus ($bn), 2007–2023

Figure 18: Diabetes Drugs Market, Global, And Annual Revenues for Tradjenta ($m), 2011–2023

Figure 19: Diabetes Drugs Market, Global Annual Revenues for Invokana ($bn), 2013–2023

Figure 20: Diabetes Drugs Market, Global Annual Revenue for Jardiance ($bn), 2014–2023

Figure 21: Diabetes Drugs Market, Global Annual Revenue for Farxiga ($bn), 2013–2023

Figure 22: Diabetes Drugs Market, Global Annual Revenues for Soliqua 100/33 ($m), 2017–2023

Figure 23: Diabetes Drugs Market, Global Annual Revenue for Xultophy ($bn), 2017–2023

Figure 24: Diabetes Drugs Market, Global Annual Revenue for Janumet ($bn), 2007–2023

Figure 25: Diabetes Drugs Market, Global Annual Revenue for Qtern ($m), 2017–2023

Figure 26: Diabetes Drugs Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2017

Figure 27: Diabetes Drugs Market, Global, Pipeline by Stage of Development, Molecule Type and Program Type, 2017

Figure 28: Diabetes Drugs Market, Global, T1DM and T2DM Pipeline by Stage of Development, 2017

Figure 29: Diabetes Drugs Market, Global, T1DM and T2DM Pipeline by Molecule Type, 2017

Figure 30: Diabetes Drugs Market, Global, Pipeline by Molecular Target, 2017

Figure 31: Diabetes Drugs Market, Global, T1DM and T2DM Pipeline by Molecular Target, 2017

Figure 32: Diabetes Drugs Market, Clinical Trial Failure Rates by Stage of Development and Overall Clinical Trial Attrition Rate (%), 2006–2017

Figure 33: Diabetes Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rates by Indication (%), 2006–2017

Figure 34: Diabetes Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rate by Molecule Type (%), 2006–2017

Figure 35: Diabetes Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rate by Molecular Target (%), 2006–2017

Figure 36: Diabetes Drugs Market, Global, Clinical Trial Duration by Stage of Development (months), 2006–2017

Figure 37: Diabetes Drugs Market, Global, Clinical Trial Duration by Indication and Stage of Development (months), 2006–2017

Figure 38: Diabetes Drugs Market, Global, Clinical Trial Duration by Molecule Type and Stage of Development (months), 2006–2017

Figure 39: Diabetes Drugs Market, Global, Clinical Trial Duration by Molecular Target and Stage of Development (months), 2006–2017

Figure 40: Diabetes Drugs Market, Global, Clinical Trial Size by Stage of Development, 2006–2017

Figure 41: Diabetes Drugs Market, Global, Clinical Trial Size by Indication and Stage of Development (participants), 2006–2017

Figure 42: Diabetes Drugs Market, Global, Clinical Trial Size by Molecule Type and Stage of Development (participants), 2006–2017

Figure 43: Diabetes Drugs Market, Global, Clinical Trial Size by Molecular Target and Stage of Development (Participants), 2006–2017

Figure 44: Diabetes Drugs Market, Global, Aggregate Clinical Program Size by Stage of Development, 2006–2017

Figure 45: Diabetes Drugs Market, Global, Aggregate Clinical Program Size by Indication and Stage of Development (participants), 2006–2017

Figure 46: Diabetes Drugs Market, Global, Aggregate Clinical Program Size by Molecule Type and Stage of Development (participants), 2006–2017

Figure 47: Diabetes Drugs Market, Global, Aggregate Clinical Program Size by Molecular Target and Stage of Development (participants), 2006–2017

Figure 48: Diabetes Drugs Market, Global, Revenue Forecast for Semaglutide (NN-9535) ($bn), 2017–2023

Figure 49: Diabetes Drugs Market, Global, Revenue Forecast for Oral Semaglutide (OG-217SC) ($bn), 2020–2023

Figure 50: Diabetes Drugs Market, Global, Revenue Forecast for ITCA 650 ($bn), 2018–2023

Figure 51: Diabetes Drugs Market, Global, Revenue Forecast for Sotagliflozin ($bn), 2018–2023

Figure 52: Diabetes Drugs Market, Global, Revenue Forecast for Ertugliflozin ($m), 2017–2023

Figure 53: Diabetes Drugs Market, Global Annual Revenue Forecast, 2018–2023

Figure 54: Diabetes Drugs Market, Global Annual Revenue Forecast for Premium and Generic Products ($bn), 2018–2023

Figure 55: Diabetes Drugs Market, Global Annual Revenue Forecast for Insulin Receptors ($bn), 2018–2023

Figure 56: Diabetes Drugs Market, Global Annual Revenue Forecast for GLP-1 Receptors, 2018–2023

Figure 57: Diabetes Drugs Market, Global Annual Revenue Forecast for SGLT-2 Inhibitors, 2018–2023

Figure 58: Diabetes Drugs Market, Global Annual Revenue Forecast for DPP-4 Inhibitors, 2018–2023

Figure 59: Diabetes Drugs Market, Global, Cluster by Growth and Market Share, 2018–2023

Figure 60: Diabetes Drugs Market, Global, Forecast Market Share by Company (%), 2018–2023

Figure 61: Diabetes Drugs Market Global, Companies by Compound Annual Growth Rate (%), 2018–2023

Figure 62: Diabetes Drugs Market, Global, Revenue by Route of Acquisition, 2018–2023

Figure 63: Diabetes Drugs Market, Global, Novo Nordisk and Annual Revenue Forecast, ($bn), 2018–2023

Figure 64: Diabetes Drugs Market, Global, Eli Lilly and Annual Revenue Forecast ($bn), 2018–2023

Figure 65: Diabetes Drugs Market, Global, Sanofi and Annual Revenue Forecast ($bn), 2018–2023

Figure 66: Diabetes Drugs Market, Global, AstraZeneca and Annual Revenue Forecast ($bn), 2018–2023

Figure 67: Diabetes Drugs Market, Global, Johnson & Johnson and Annual Revenue Forecast ($bn), 2018–2023

Figure 68: Diabetes Drugs Market, Global, Merck and Co and Annual Revenue Forecast ($bn), 2018–2023

Figure 69: Diabetes Drugs Market, Global, High-activity and Late-stage Pipeline Developers by Company Type, 2018–2023

Figure 70: Diabetes Drugs Market, Global, Pipeline Developers by Level of Diabetes Specialization, 2018–2023

Figure 71: Diabetes Drugs Market, Global, Proportion of Total Company Revenue Attributable to Diabetes, 2018–2023

Figure 72: Diabetes Drugs Market, Licensing Deals by Region, Value and Year, 2006–2017

Figure 73: Diabetes Drugs Market, Global, Number of Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006–2017

Figure 74: Diabetes Drugs Market, Global, Licensing Deals by Molecule Type and Molecular Target, 2006–2017

Figure 75: Diabetes Drugs Market, Global, Licensing Deals Valued at $100m and above, 2006–2017

Figure 76: Diabetes Drugs Market, Global, Co-development Deals Valued at $100m and above, 2006–2017

Figure 77: Diabetes Drugs Market, Global, Co-development Deals by Region, Value and Year, 2006–2017

Figure 78: Diabetes Drugs Market, Global, Number of Co-development Deals by Value and Stage of Development, 2006–2017

Figure 79: Diabetes Drugs Market, Global, Co-development Deals by Molecule Type and Molecular Target, 2006–2017


View details
Please fill your details below, to inquire about this report:
Indicates required fields
Please fill your details below, to receive sample report:
Indicates required fields
Latest News

25-Feb-2019 | ICT and Media

Fed Says Due To Surged Financial Volatility, US Labor Market Tightens

Recently, in its new report on the economy, the Fed (Federal Reserve) said that labor market is tightened in the U.S. as businesses are struggling to find workers at any expertise level and wages usually grew moderately. The Fed’s “Beige Book” report—which is a picture of the economy picked up from conversations with business contacts—reported that stiff labor m ...

25-Feb-2019 | Electrical & Electronic

Global Battery Material Market Finds A Ray Of Hope In The Structural Battery

Batteries are generally made using lithium or others ions which are not only harmful to the environment but also difficult to find or manufacture. However, a team from the University of Michigan has successfully developed a new material for batteries stating that the knees and smartphones have similar needs. The structural battery prototype possessing cartilage-inspired materials can actuall ...

13-Feb-2019 | Electrical & Electronic

Absolute Regulation Would Motivate The Growth Of UAV Market

The drone industry will grow rapidly with increased use of drones in areas such as agriculture, mining, construction, resource exploration, and supervision. By 2018, drone companies have begun to expand their scope and determine the feasibility of a drone program by reorganizing their workflows and managing the data. This year, companies are expected to focus on their strategies and benefit ...

13-Feb-2019 | Machinery & Equipments

Acquirement of Structured Polymers By Evonik To Bring New Opportunities In 3D Printing Materials Market

Evonik has procured a tech startup based in the United States for 3D printing materials: Structured Polymers Inc. A conforming agreement and plot of the merger were accomplished and the deal has been sealed recently. The procurement will offer access to Evonik to the new patented technology that will enable the firm to extend its range of specialty polymer powders within the additive manufac ...

05-Feb-2019 | Medical & Health

A New Sensor Platform Opens Up Diverse Doors For Smart Medical Devices Market

Recently, a group of researchers from the University of Bath and Northwestern University has produced the latest type of sensor platform with an array of gold nanoparticles. The sensors are believed to have a vital role to play in the field of smart medical devices market in order to help make sensitivity related tasks simpler as well as quicker for the medical staff.